Last Updated: August 8, 2026

Claims for Patent: 12,605,385

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,605,385

Title:	Methotrexate formulation
Abstract:	A liquid pharmaceutical composition comprises methotrexate free acid and a buffer, wherein the pH of the composition is in the range of 6.5 to 8.2. Processes for preparation of the liquid pharmaceutical composition are also described. The liquid pharmaceutical composition is useful in therapy.
Inventor(s):	Michael Frodsham, Julie-Ann PENTON
Assignee:	Shorla Pharma Ltd , Shorla Pharma Ltd T/a Shorla Oncology
Application Number:	US18/374,215
Patent Claims:	1. A liquid pharmaceutical composition comprising: methotrexate free acid, 2 to 6 mg/ml polyethylene glycol, and a buffer, wherein the pH of the composition is in the range of 6.6 to 7.0, and wherein the buffer strength is between 0.02 to 0.06 M. 2. The composition of claim 1, further comprising glycerol. 3. The composition of claim 2, comprising 50 to 200 mg/ml glycerol. 4. The composition of claim 1, wherein the polyethylene glycol is PEG 400. 5. The composition of claim 1, wherein the amount of methotrexate ranges from 0.4 mg/ml to 20 mg/ml. 6. The composition of claim 5, wherein the amount of methotrexate ranges from 1 mg/ml to 5 mg/ml. 7. The composition of claim 1, wherein the pH is about 6.6, about 6.7, about 6.8, or about 6.9. 8. The composition of claim 1, wherein the pH is about 6.8. 9. The composition of claim 1, wherein the buffer strength is between 0.02 M to 0.05 M. 10. The composition of claim 9, wherein the buffer strength is about 0.05M. 11. The composition of claim 1, further comprising one or more flavor and sweetener, wherein the flavor is orange or berry, and the sweetener is sucralose. 12. The composition of claim 1, further comprising one or more preservatives selected from and ethyl parahydroxybenzoate methyl parahydroxybenzoate sodium salt. 13. The composition of claim 1, wherein the buffer is sodium citrate buffer. 14. The composition of claim 13, wherein the sodium citrate buffer comprises tri-sodium citrate, citric acid, and water. 15. The composition of claim 1, further comprising glycerol and methyl parahydroxybenzoate sodium salt, wherein the buffer is sodium citrate buffer. 16. The composition of claim 1, comprising 0.4 mg/ml to 20 mg/ml methotrexate, 2 to 6 mg/ml polyethylene glycol, and a citrate buffer having a buffer strength of 0.02 M to 0.06 M, wherein the pH is about 6.8.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.